CoChat

Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Open access
de Boer, Ian H., for the DCCT/EDIC Research Group · 2014 · Diabetes Care

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Kidney disease manifests clinically as elevated albumin excretion rate (AER), impaired glomerular filtration rate (GFR), or both, and is a cause of substantial morbidity and mortality in type 1 diabetes (T1D). The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study tested whether intensive diabetes therapy (INT) aimed at lowering glucose concentrations as close as safely possible to the normal range reduces the risks of kidney disease and other diabetes complications. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants with T1D were randomly assigned to INT or conventional diabetes therapy (CON) for a mean duration of 6.5 years. Subsequently, participants have been followed for 18 years in the ongoing observational EDIC. Standardized longitudinal measurements of AER, estimated GFR, and blood pressure were made throughout the DCCT/EDIC. RESULTS: During the DCCT, INT reduced the risks of incident microalbuminuria (AER ≥40 mg/24 h) and macroalbuminuria (AER ≥300 mg/24 h) by 39% (95% CI 21–52%) and 54% (29–74%), respectively. During EDIC years 1–8, participants previously assigned to DCCT INT continued to experience lower rates of incident microalbuminuria and macroalbuminuria, with risk reductions of 59% (39–73%) and 84% (67–92%), respectively. Beneficial effects of INT on the development of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) and hypertension became evident during combined DCCT/EDIC follow-up, with risk reductions of 50% (18–69%) and 20% (6–21%), respectively, compared with CON. CONCLUSIONS: In the DCCT/EDIC, INT resulted in clinically important, durable reductions in the risks of microalbuminuria, macroalbuminuria, impaired GFR, and hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-2113

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cumulative incidence of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) by DCCT treatment group, accounting for death as a competing risk. Reproduced with permission from de Boer et al. (12).
Figure 1 Cumulative incidence of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) by DCCT treatment group, accounting for death as a competing risk. Reproduced with permission from de Boer et al. (12).CC BY-NC-ND · PubMed Central
Figure 2 Cumulative incidence of hypertension (two consecutive study visits with systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or the use of antihypertensive medications) by DCCT treatment assignment. Reproduced with permission from de Boer et al. (14).
Figure 2 Cumulative incidence of hypertension (two consecutive study visits with systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or the use of antihypertensive medications) by DCCT treatment assignment. Reproduced with permission from de Boer et al. (14).CC BY-NC-ND · PubMed Central
Figure 3 Cumulative incidence of persistent microalbuminuria (AER ≥30 mg/24 h on two consecutive study visits) in the DCCT/EDIC, by duration of T1D and DCCT treatment assignment. Reproduced with permission from de Boer et al. (15).
Figure 3 Cumulative incidence of persistent microalbuminuria (AER ≥30 mg/24 h on two consecutive study visits) in the DCCT/EDIC, by duration of T1D and DCCT treatment assignment. Reproduced with permission from de Boer et al. (15).CC BY-NC-ND · PubMed Central
Figure 4 Cumulative incidence of long-term renal outcomes after the development of persistent microalbuminuria (AER ≥30 mg/24 h on two consecutive study visits, defining time 0) among 325 participants in the DCCT/EDIC. Normoalbuminuria (AER <30 mg/24 h on two consecutive study visits), macroalbuminuria (AER ≥300 mg/24 h), impaired GFR (estimated GFR <60 mL/min/1.73 m2 on two consecutive study visits), and ESRD are evaluated as parallel outcomes and are not mutually exclusive. Reproduced with permission from de Boer et al. (15).
Figure 4 Cumulative incidence of long-term renal outcomes after the development of persistent microalbuminuria (AER ≥30 mg/24 h on two consecutive study visits, defining time 0) among 325 participants in the DCCT/EDIC. Normoalbuminuria (AER <30 mg/24 h on two consecutive study visits), macroalbuminuria (AER ≥300 mg/24 h), impaired GFR (estimated GFR <60 mL/min/1.73 m2 on two consecutive study visits), and ESRD are evaluated as parallel outcomes and are not mutually exclusive. Reproduced with permission from de Boer et al. (15).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Metadata

Authors
de Boer, I. H., & for the DCCT/EDIC Research Group
Affiliations
Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA
Venue
Diabetes Care
Published
2013-12-11
Volume
37
Issue
1
Pages
24-30
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2160388935
Cited by
254
References
38
Citations by year
2026: 9 · 2025: 18 · 2024: 20 · 2023: 26 · 2022: 28 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 16 · 2017: 12 · 2016: 16 · 2015: 27 · 2014: 11 · 2013: 3
FWCI
14.40
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
  • National Eye Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, RC4DK090766, R01DK088762, P30DK017047)
  • National Institute of Neurological Disorders and Stroke
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 1 diabetes, diabetic nephropathy, urinary albumin excretion rate, microalbuminuria, macroalbuminuria, glomerular filtration rate, intensive diabetes therapy, glycemic control, hypertension, DCCT/EDIC
MeSH terms
Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypertension, Insulin, Kidney, Male, Middle Aged, Risk Factors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.